首页> 外文期刊>Molecular BioSystems >Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection
【24h】

Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection

机译:中药治疗上呼吸道感染机理的网络药理研究

获取原文
获取原文并翻译 | 示例
           

摘要

Traditional Chinese medicine (TCM) is a multi-component and multi-target agent and could treat complex diseases in a holistic way, especially infection diseases. However, the underlying pharmacology remains unclear. Fortunately, network pharmacology by integrating system biology and polypharmacology provides a strategy to address this issue. In this work, Reduning Injection (RDN), a well-used TCM treatment in the clinic for upper respiratory tract infections (URTIs), was investigated to interpret the molecular mechanism and predict new clinical directions by integrating molecular docking, network analysis and cell-based assays. 32 active ingredients and 38 potential targets were identified. In vitro experiments confirmed the bioactivities of the compounds against lipopolysaccharide (LPS)-stimulated PGE_2 and NO production in RAW264.7 cells. Moreover, network analysis showed that RDN could not only inhibit viral replication but also alleviate the sickness symptoms of URTIs through directly targeting the key proteins in the respiratory viral life cycle and indirectly regulating host immune systems. In addition, other clinical applications of RDN such as neoplasms, cardiovascular diseases and immune system diseases were predicted on the basis of the relationships between targets and diseases.
机译:中药是一种多成分,多靶点的药物,可以全面治疗复杂疾病,尤其是感染性疾病。但是,基本药理学尚不清楚。幸运的是,通过结合系统生物学和多元药学,网络药理学提供了解决此问题的策略。在这项工作中,研究了Reduning Injection(RDN),这是临床上用于上呼吸道感染(URTIs)的一种常用中药治疗方法,通过整合分子对接,网络分析和细胞分析来解释分子机制并预测新的临床方向。基于基础的分析。确定了32种有效成分和38个潜在目标。体外实验证实了该化合物对脂多糖(LPS)刺激的PGE_2的生物活性以及RAW264.7细胞中NO的产生。此外,网络分析表明,RDN不仅可以通过直接靶向呼吸病毒生命周期中的关键蛋白并间接调节宿主免疫系统来抑制病毒复制,而且还可以缓解URTIs的疾病症状。此外,根据目标与疾病之间的关系,还预测了RDN的其他临床应用,例如肿瘤,心血管疾病和免疫系统疾病。

著录项

  • 来源
    《Molecular BioSystems》 |2014年第10期|2517-2525|共9页
  • 作者单位

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

    Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P.R. China;

    Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P.R. China;

    State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Kanion Pharmaceutical Corporation, Lianyungang City 222002, P.R. China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号